CBD Stocks on The Rebound

HENDERSON, NV / ACCESSWIRE / November 6, 2018 / As the stock market plummeted early October cannabis companies stayed strong, buoyed up by legislative changes in Canada. The cannabis market appears set for continuing growth as it expands into expected sales worth billions of dollars across North America. While it still faces regulatory challenges in some locations, this market sector is preparing for corporate big players to move in.

Looking at options in the space Chineseinvestors.com Inc. (CIIX) is one of the more intriguing CBD companies. Focused on the sales of industrial hemp-based CBD products in China, the company just reported impressive numbers including 70% increase in revenue and an 800% sales increase. CIIX also presented these impressive numbers at the NIBA investment conference last week and could see a spike in activity over the next couple weeks based on the increased exposure. Do your due diligence on CIIX today.

CBD stocks to watch include: ChineseInvestors.com, Inc. (CIIX), Cronos Group, Inc. (CRON), GW Pharmaceuticalas plc (GWPH), MariMed, Inc. (MRMD), and CV Sciences, Inc. (CVSI).

ChineseInvestors.com, Inc. (CIIX)

Market Cap: $24.72M Share Price: $0.67

ChineseInvestors.com, Inc. (CIIX) presented at the National Investment Banking Association (NIBA) 145th investment conference, this past week at the Crowne Plaza Times Square in New York City.

NIBA has been connecting companies with funding and liquidity sources for over 35 years, with a successful track record that includes raising (USD) billions for micro-cap and small-cap companies.

Cronos Group, Inc. (CRON)

Market Cap: $1.43B Share Price: $8.06

CRON will announce its financial results and hold its Third Quarter 2018 Earnings Conference Call on Tuesday, November 13, 2018, at 8:30 a.m. EDT. Senior management will be available for questions from the investment community after prepared remarks.

GW Pharmaceuticals plc (GWPH)

Market Cap: $4.71B Share Price: $145.71

GW Pharmaceuticals (GWPH) announced that its EPIDIOLEX^® (cannabidiol) oral solution CV is now available in the U.S. for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018, is the first prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs.

MariMed, Inc. (MRMD)

Market Cap: $935.14M Share Price: $4.79

MariMed, Inc., a professional cannabis organization that develops cannabis facilities and brands of cannabis infused products in multiple states throughout the US, announced it had consummated its strategic investment in Sprout, an all-in-one CRM and marketing software company for marijuana dispensaries and cannabis brands. This completes the previously announced MariMed LOI for investment in Cannabis Venture Partners, parent company of Sprout.

CV Sciences, Inc. (CVSI)

Market Cap: $555.35M Share Price: $5.81

CVSI announced that it will be a Title Sponsor of the 25th anniversary of HIACON Conference on November 2-5, in Los Angeles, California. Produced by the Hemp Industries Association (HIA), HIACON will bring together over 400 attendees (cultivators, stakeholders, buyers), more than 55 speakers and industry thought leaders, and many other hemp and CBD sponsors to the Hilton Los Angeles Airport Hotel.

Important Disclaimer, Please Read:

The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.

The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.

Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. CIIX has paid forty-nine thousand dollars and twenty thousand restricted shares for corporate awareness services for the month of October, and continues to pay Regal to disseminate truthful and potentially material information regarding CIIX.

Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.

Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.

Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in CIIX can be found updated here: http://www.regalconsultingllc.com/disclaimer/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and nineteen thousand dollars total by Regal Consulting. LLC, for news commentary articles for CIIX. CIIX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. We may buy or sell additional shares of CIIX in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: Microcap Speculators